Metro (MRU) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Q4 sales were CAD 4.94 billion, down 2.6% year-over-year, but up 5.7% on a comparable 12-week basis due to last year's labor disruption and extra week.
Same-store sales rose 2.2% in food and 5.7% in pharmacy, with online food sales up 27.6% year-over-year for the comparable 12-week period.
Fiscal 2024 sales reached $21.2 billion, up 2.4% year-over-year, and adjusted net earnings were $972.9 million, down 3.3%.
Supply chain modernization, a seven-year, nearly CAD 1 billion investment, was completed, including new automated distribution centers in Ontario and Quebec.
Moi Rewards launched in Ontario, gaining over 1 million members in under four weeks.
Financial highlights
Gross margin improved to 19.7% from 19.5% year-over-year.
Operating expenses were 10.4% of sales, down from 10.7% last year.
EBITDA reached CAD 459.6 million (9.3% of sales), up 2.6% year-over-year.
Adjusted net earnings were CAD 226.5 million in Q4 (down 1% year-over-year); adjusted EPS rose 3% to CAD 1.02.
Fiscal 2024 net earnings were $931.7 million (down 8.5%), and adjusted EPS was $4.30 (unchanged year-over-year).
Outlook and guidance
Fiscal 2024 results met guidance; gradual profit growth expected in 2025.
Medium/long-term targets: sales growth of 2%-4%, operating income growth of 4%-6%, and adjusted EPS growth of 8%-10%.
Inflation expected to normalize around 2% in 2025.
CapEx for 2025 projected at CAD 550-600 million, with some 2024 projects rolling over.
Latest events from Metro
- Q2 sales up 5.5%, adjusted EPS up 12.1%, and online sales grew 26.2% year-over-year.MRU
Q2 20259 Jul 2026 - Sales up 3.5% to CAD 6.65B, but net earnings fell 14.6% amid automation and cost pressures.MRU
Q3 20249 Jul 2026 - Strong results, board re-elections, and strategic growth plans highlighted; auditor term limit proposal rejected.MRU
AGM 20258 Jul 2026 - Q2 sales rose 4.1% to CAD 5.1B, with strong pharmacy, discount, and online growth.MRU
Q2 202622 Apr 2026 - Sales up 2.9%, adjusted EPS up 7.8%, online sales up 18.6%, and dividend raised 10.4%.MRU
Q1 20254 Mar 2026 - Q3 sales rose 3.3%, adjusted EPS up 12.6%, with strong pharmacy and discount banner growth.MRU
Q3 20254 Mar 2026 - Q4 sales and earnings rose despite supply chain disruptions, with a strong FY 2026 outlook.MRU
Q4 20254 Mar 2026 - Sales up 3.3%, adjusted EPS up 5.5%, net earnings down 12.8% on one-time costs; dividend up 10.1%.MRU
Q1 20264 Mar 2026